Letter to Gilead and Senior Federal Health Officials Calling for Immediate Study of the Antiviral Drug GS-441524 as a Potential Treatment for COVID-19

View as PDF

View press release

In a letter to leadership of Gilead Sciences, Inc., the National Institutes of Health, the Food and Drug Administration, and the Biomedical Advanced Research and Development Authority, Public Citizen and two scientists specializing in cancer drug development offer a detailed summary of scientific evidence suggesting that the experimental antiviral drug GS-441524 may be a better drug than the closely-related drug remdesivir to treat COVID-19. The letter asks Gilead and the federal agencies either to work collaboratively to promptly pursue the development of GS-441524 as a treatment for COVID-19 or to publicly explain and provide evidence as to why doing so is not scientifically or medically feasible.

August 20, 2020, NIH response letter.

See Public Citizen’s other work on the coronavirus pandemic.